Slate Run Pharmaceuticals recalls Eptifibatide Injection
- Published
- 4 Mar 2026
- Units affected
- N/A
- Agency
- FDA
- Country
- United States
The hazard
Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.
Classification: Class III — this product is unlikely to cause health problems but breaks FDA rules (for example labeling).
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Single-dose Vial, For Intravenous Use Only, Rx Only, Manufactured by: Hainan Poly Pharm. Co., Ltd., Guilinyang Economic Development Area, Haikou, Hainan Province, China 571127; Distributed by: Slate Run Pharmaceuticals, LLC, Columbus, Ohio 43215. NDC Slate Run Carton Label: 70436-027-80; NDC ProRx Carton Label: 70436-163-80
- Brand / company
- Slate Run Pharmaceuticals
- Codes / lots
- All lots within expiry
- Distribution
- Nationwide within the USA.
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 4 Mar 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.